Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised study reduces patient enrollment from 390 to 126, lowering costs from over $30 million to under $10 million while maintaining scientific rigor. The FDA's feedback focused on operational details rather than core study design, allowing the company to proceed with patient recruitment soon. This streamlined approach improves efficiency and includes an interim analysis to monitor progress, marking a positive step forward for the drug's development.
The 2026 Enbridge Tour Alberta for Cancer saw over 2,300 cyclists raise a record-breaking $12.5 million to support cancer care in Alberta. The funds will be invested by the Alberta Cancer Foundation into advanced cancer research, clinical trials, and...
In 2010, Satoshi Nakamoto defended Bitcoin's SHA-256 hashing against security doubts, establishing a plan to upgrade if needed. Despite advances in quantum computing, SHA-256 remains secure, with no successful attacks to date. Developers in 2026 prop...
DOG Mode is an alternative Bitcoin client that relaxes default relay policies affecting transactions like Ordinals and Runes without changing Bitcoin's core consensus rules. This approach reignites a debate over Bitcoin's governance, censorship, and ...
Ethereum has stayed just above $1,800 recently, a key support level, but thin trading volumes and weak investor interest suggest the current rally may be short-lived. Positive net inflows into Ethereum ETFs in July indicate some renewed interest, yet...
Rap superstar Drake placed a $1.5 million bet in USDT on Argentina to beat Spain in the FIFA World Cup final, potentially winning about $5.175 million if Argentina wins in regulation or extra time. Despite Spain being the favorite in prediction marke...
